Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.35 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.34 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.34 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.34 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.33 |
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21743003 | 0.91 | MAPK1 (0.39) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL14113910 | 0.88 | LGALS3 (0.43) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL16016954 | 0.83 | CD69 (0.43) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL25963088 | 0.82 | MAPK1 (0.44) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL13994673 | 0.81 | MAPK1 (0.41) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL23322444 | 0.80 | LGALS3 (0.43) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL18608226 | 0.80 | LGALS3 (0.43) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL18608138 | 0.80 | LGALS3 (0.43) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL25024613 | 0.79 | MAPK1 (0.37) | MAPK1CD69LGALS3ALDH1A1THRB | |
| SCHEMBL14089003 | 0.77 | ALDH1A1 (0.48) | MAPK1CD69LGALS3ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | TAMBO, INC. | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256109-A1 | Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy | ICOS, CD74, PBK | MAPK1 3636/4885CD69 524/4885LGALS3 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.